AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01751529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid
Description: All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
Study NCT03193255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPHTECS cleadew GP
Description: Povidone-iodine based disinfecting solutions for rigid contact lenses
Study NCT04771806 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01598311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-183,315
Description: CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
Study NCT01598311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
Study NCT01598311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo size 00 opaque hard gelatin capsules.
Study NCT02368678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planning (SRP)
Description: Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants.
Study NCT02368678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Mouth Scaling (FMS)
Description: Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants.
Study NCT00978627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
Study NCT00978627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
Study NCT00978627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
Study NCT00978627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
Study NCT02188420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study NCT02188420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study NCT02560311 — intervention group
Intervention type: OTHER
Intervention: observation
Study NCT00095498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous injection
Study NCT00095498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: For subcutaneous injection
Study NCT00346671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 30 min supine rest
Study NCT00346671 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 30 min session with Sham practitioner
Study NCT00346671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: 30 min session with Reiki practitioner
Study NCT03258684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, Vitamin C, and Thiamine
Description: Intervention
Study NCT03258684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT02301715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Study NCT02301715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Study NCT02666469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy (HBOT) and Exercise Program
Description: HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
Study NCT02666469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
Study NCT02666469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Multiplace Chamber
Description: Patients will receive treatment in a multiplace Hyperbaric Chamber
Study NCT02708654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
Study NCT02708654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bluetooth scale
Description: Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
Study NCT02708654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Partner
Description: Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
Study NCT02708654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement incentives
Description: Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
Study NCT03620331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with a previous non-surgical approach
Description: Non-surgical phase done prior to the surgical treatment of peri-implantitis
Study NCT03620331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery without a previous non-surgical approach
Description: Non-surgical phase not done prior to the surgical treatment of peri-implantitis
Study NCT02946190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertagen® aP + Td-pur®
Description: see arm/group descriptions
Study NCT02946190 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix® dTpa
Description: see arm/group descriptions
Study NCT04351737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracanalicular Dexamethasone, (0.4 mg) Insert
Description: To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
Study NCT04351737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate
Description: To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
Study NCT00055601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
Study NCT00055601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
Study NCT00055601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
Study NCT00055601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
Study NCT00055601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
Study NCT00055601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
Study NCT00452426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)
Description: propofol sedation per device instructions for use
Study NCT00452426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: benzodiazepines and opioid sedation
Description: per site's current standard of care
Study NCT03541174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 12.5 mg
Description: Tablet, oral use
Study NCT03541174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use
Study NCT03541174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox
Description: 25mg aspirin, 200 mg dipyridamole
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel placebo
Description: placebo
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis
Description: 80 mg micardis
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox placebo
Description: placebo
Study NCT04771806 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive testing
Study NCT04771806 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04771806 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00732056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN163L
Description: 25% dose escalation infused over 2 hours weekly
Study NCT04466943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular transmission monitoring (NMT)
Description: NMT is to monitor the depth of neuromuscular blockade intensity
Study NCT01751698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASP-EMT
Description: JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
Study NCT01751698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTT
Description: CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
Study NCT01409707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused exposure therapy
Description: cognitive behavioral therapy for PTSD
Study NCT01409707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement + trauma-focused exposure therapy
Description: Cognitive behavioral therapy for PTSD
Study NCT01409707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyles sessions
Study NCT02220920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 16 weeks
Study NCT02220920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive Placebo orally for 16 weeks
Study NCT02220920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT02220920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study NCT01213563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid insulin+Gloucose
Description: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
Study NCT01213563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid insulin
Description: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
Study NCT01796808 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pedal Fat Grafting
Description: Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity.
Study NCT01796808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local anesthetic
Description: To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. \<200ml). Only a few cc's of fat are needed for injection into the foot.
Study NCT00648440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl Tablets 5 mg
Description: 5mg, single dose fed
Study NCT00648440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAmatine® Tablets 5 mg
Description: 5mg, single dose fed
Study NCT01646580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclopirox
Description: Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
Study NCT04611386 — intervention group
Intervention type: DRUG
Intervention: computerized tomography
Description: Anti Factor Xa level
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folic acid placebo
Description: folic acid placebo 1 tablet QD
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid placebo
Description: folic acid placebo 1 tablet QD
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine placebo
Description: mirtazapine placebo 1 tablet QD
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine placebo
Description: mirtazapine placebo 1 tablet QD
Study NCT01263080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: folic acid 0.4mg QD
Study NCT02183662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg clopidogrel
Study NCT02183662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 224436
Study NCT03525236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tasting of flavours
Description: * Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes
Study NCT00153062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis placebo
Description: placebo
Study NCT03760094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colour Doppler
Description: evaluation of lymph nodes by Doppler
Study NCT03711513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.